Patents by Inventor Shoumo Bhattacharya

Shoumo Bhattacharya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240034757
    Abstract: The described invention relates to tick chemokine binding polypeptides (tick CKBPs, typically tick Evasins) including hybrid CKBPs based on sequences from two or more tick CKBPs, and the uses of such polypeptides in inhibition of chemokines or detection of chemokine expression and inflammation.
    Type: Application
    Filed: January 12, 2023
    Publication date: February 1, 2024
    Applicant: Oxford University Innovation Limited
    Inventor: Shoumo Bhattacharya
  • Publication number: 20220175942
    Abstract: The invention relates to novel Evasin polypeptides with novel chemokine-binding properties and their use in inhibiting chemokines or detecting chemokine expression and inflammation.
    Type: Application
    Filed: August 16, 2021
    Publication date: June 9, 2022
    Inventor: Shoumo Bhattacharya
  • Publication number: 20200247855
    Abstract: The described invention relates to tick chemokine binding polypeptides (tick CKBPs, typically tick Evasins) including hybrid CKBPs based on sequences from two or more tick CKBPs, and the uses of such polypeptides in inhibition of chemokines or detection of chemokine expression and inflammation.
    Type: Application
    Filed: February 7, 2020
    Publication date: August 6, 2020
    Inventor: Shoumo Bhattacharya
  • Publication number: 20190077839
    Abstract: The invention relates to novel Evasin polypeptides with novel chemokine-binding properties and their use in inhibiting chemokines or detecting chemokine expression and inflammation.
    Type: Application
    Filed: March 2, 2017
    Publication date: March 14, 2019
    Inventor: Shoumo Bhattacharya
  • Publication number: 20080113993
    Abstract: This invention pertains to active barbituric acid analogs which inhibit HIF-1 activity (e.g., the interaction between HIF-1$g(a) and p300) and thereby inhibit angiogenesis, tumorigenesis, and proliferative conditions, such as cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HIF-1 activity, and to inhibit angiogenesis, tumorigenesis, and proliferative conditions, such as cancer.
    Type: Application
    Filed: January 16, 2008
    Publication date: May 15, 2008
    Applicant: Via Ariosto, 23
    Inventors: Jackie DE BELIN, Maria-Rosario Romero-Martin, Paul Finn, Lee Sayers, Norman Law, David Billington, Stephen Ryley, Shoumo Bhattacharya
  • Publication number: 20060172323
    Abstract: The invention provides methods for identifying compounds that can be used to modify transcriptional responses to hypoxia, and use of such compounds in therapeutic and diagnostic methods.
    Type: Application
    Filed: October 28, 2005
    Publication date: August 3, 2006
    Inventors: David Livingston, Andrew Kung, Shoumo Bhattacharya
  • Patent number: 6986881
    Abstract: The invention provides methods for identifying compounds that can be used to modify transcriptional responses to hypoxia, and use of such compounds in therapeutic and diagnostic methods.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: January 17, 2006
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: David M. Livingston, Andrew L. Kung, Shoumo Bhattacharya
  • Publication number: 20040053231
    Abstract: Novel transcription transactivator protein of the CITED family, designated HCITEDX. Nucleic acids encoding the protein and uses of the protein are also provided.
    Type: Application
    Filed: September 17, 2002
    Publication date: March 18, 2004
    Inventors: Shoumo Bhattacharya, Jose Braganca, Tracey Swingler
  • Publication number: 20030229108
    Abstract: This invention pertains to active barbituric acid analogs which inhibit HIF-1 activity (e.g., the interaction between HIF-1&agr; and p300) and thereby inhibit angiogenesis, tumorigensis, and proliferative conditions, such as cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HIF-1 activity, and to inhibit angiogensis, tumorigensis, and proliferative conditions, such as cancer.
    Type: Application
    Filed: May 21, 2003
    Publication date: December 11, 2003
    Inventors: Jackie Y De Belin, Maria-Rosario Romero-Martin, Paul W Finn, Lee G Sayers, Norman M Law, David C Billington, Stephen Ryley, Shoumo Bhattacharya